RIGL Earning Date, Earning Analysis and Earning Prediction
Earning Analysis
Welcome to our in-depth analysis of Rigel Pharmaceuticals Inc(RIGL) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Rigel Pharmaceuticals Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
Name
EPS
Revenue
Price Reaction
Fiscal Quarter
Earning Date
Time
Estimate
Actual
Surprise%
Estimate
Actual
Surprise%
1D
5D
FY2025Q3
2025-11-04
After Hours
0.93
1.46
+56.99
61.88M
69.46M
+12.25
+33.37
+21.74
FY2025Q2
2025-08-05
After Hours
1.97
3.28
+66.50
72.58M
101.69M
+40.10
+22.98
+38.04
FY2025Q1
2025-05-06
After Hours
0.14
0.63
+350.00
43.87M
53.33M
+21.56
+1.15
+1.92
FY2024Q4
2025-03-04
After Hours
0.55
0.80
+45.45
57.59M
57.60M
+0.01
-8.11
-11.73
FY2024Q2
2024-08-06
-
-0.37
-0.06
+83.78
33.70M
36.84M
+9.31
+6.02
+27.84
FY2024Q1
2024-05-07
-
-0.03
-0.05
-66.67
31.47M
29.53M
-6.16
-2.46
-19.67
FY2023Q4
2024-03-05
-
-0.03
0.00
+100.00
33.42M
35.79M
+7.11
+0.68
+2.72
FY2023Q3
2023-11-07
-
-0.07
-0.03
+57.14
27.20M
28.13M
+3.43
+3.57
-4.76
FY2023Q2
2023-08-01
-
-0.08
-0.04
+50.00
25.70M
26.89M
+4.60
-3.62
-13.77
-
2023-05-02
-
-0.09
-0.08
+11.11
-
-
-
-4.20
-
RIGL Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Rigel Pharmaceuticals Inc reported performance for FY2025Q3, announced on 2025-11-04. The company achieved an EPS of 1.46, compared to analyst estimates of 0.93 by 56.99% . Revenue for the quarter reached 69.46M compared to expectations of 61.88M by 12.25% .
The stock price reacted with a 33.37% one-day change and a 21.74% five-day change following the earnings release. These movements reflect market reaction in Rigel Pharmaceuticals Inc growth trajectory and strategic initiatives.
RIGL Earnings Forecast
Looking ahead, Rigel Pharmaceuticals Inc(RIGL) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 66.44M and an EPS of 1.06.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 3.5%, while EPS estimates have been Revise Upward by 14.95%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 2.59% . These revisions correlate with a 11.77% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Rigel Pharmaceuticals Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between RIGL's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+3.5%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+14.95%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+2.59%
In Past 3 Month
Stock Price
Go Up
+11.77%
In Past 3 Month
1Y
3Y
5Y
Currency: USD
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:290.94M
--
EPS Estimate-Annual FY 2025:6.32
—
Stock Price41.69
RIGL Revenue and EPS Performance: A Historical Perspective
Rigel Pharmaceuticals Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-04,After Hours):
EPS: 1.46 (Actual) vs.0.93 (Estimate) (56.99%)
Revenue: 69.46M (Actual) vs. 61.88M (Estimate) (12.25%)
Price Reaction:33.37%(1-Day), 21.74%(5-Day)
FY2025Q2 (2025-08-05,After Hours):
EPS: 3.28 (Actual) vs.1.97 (Estimate) (66.50%)
Revenue: 101.69M (Actual) vs. 72.58M (Estimate) (40.10%)
Price Reaction:22.98%(1-Day), 38.04%(5-Day)
FY2025Q1 (2025-05-06,After Hours):
EPS: 0.63 (Actual) vs.0.14 (Estimate) (350.00%)
Revenue: 53.33M (Actual) vs. 43.87M (Estimate) (21.56%)
Price Reaction:1.15%(1-Day), 1.92%(5-Day)
Earnings Reaction
The chart below shows how RIGL performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RIGL sees a -3.86% change in stock price 10 days leading up to the earnings, and a +13.43% change 10 days following the report. On the earnings day itself, the stock moves by -0.62%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 33.37% on the day following the earnings release and then changed by 62.86% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
People Also Watch
Frequently Asked Questions
What were the key highlights of RIGL's latest earnings report for FY2025Q3?
RIGL reported its FY2025Q3 earnings on 2025-11-04, showcasing a revenue of 69.46M against an estimate of 61.88M, resulting in a 12.25% surprise. The EPS was 1.46, surpassing the expected 0.93 by 56.99% . The stock experienced a 33.37% price change on the earnings day and a 21.74% change over the next five days, reflecting market reactions to the results.
How did RIGL's stock price react after the FY2025Q3 earnings release?
Following RIGL's FY2025Q3 earnings announcement on 2025-11-04, the stock price moved by 33.37% on the day of the release. Over the subsequent five days, it saw a 21.74% change. Historically, RIGL's stock price tends to shift by an average of -3.86% in the 10 days leading up to earnings and +13.43% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for RIGL for 2025/Q4?
For 2025/Q4, analysts estimate RIGL’s annual revenue to reach 66.44M, while the EPS is projected at 1.06. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 3.5% and EPS estimates Revise Upward by 2.59% over the past three months, indicating analyst expectation in the company’s performance.
How does RIGL's stock price correlate with earnings forecast revisions?
The correlation between RIGL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 3.5%, while EPS estimates moved Revise Upward by 2.59% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from RIGL's next earnings report?
Based on historical trends, RIGL's stock price typically moves by -3.86% in the 10 days before its earnings and +13.43% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 1.06 and revenue of 66.44M.
What is the sentiment in Rigel Pharmaceuticals Inc (RIGL) Q3 2025 Earnings Call Summary?
The earnings call highlighted strong financial performance with record revenue and net income, a raised revenue guidance for 2025, and significant product sales growth. Despite some uncertainties in product development and strategic collaborations, the market reacted positively to the optimistic guidance and financial discipline. The Q&A revealed management's cautious optimism and focus on strategic growth, without major negative surprises. Given the company's small-cap status, the positive financial results and guidance are likely to drive a stock price increase in the short term.